据Hemogenyx报告,在第三名患者的试验中,治疗是安全的,没有严重的副作用. Hemogenyx reports safe treatment of third patient in trial, with no serious side effects.

PLC报告说,临床试验中的第三名病人已得到安全治疗,这是目前研究中的另一个里程碑。 Hemogenyx Pharmaceuticals PLC reported that the third patient in its clinical trial has been safely treated, marking another milestone in the ongoing study. 该公司强调,没有观察到任何严重的不利事件,从而加强了所调查治疗的安全情况。 The company emphasized that no serious adverse events were observed, reinforcing the safety profile of the treatment under investigation. 这一更新是在早先的肯定的安全数据之后进行的,支持审判工作继续取得进展。 This update follows earlier positive safety data and supports continued progress in the trial.